Aitia, founded with a mission to revolutionize drug discovery, specializes in the application of Causal AI and Digital Twins technology. The company leverages multi-omic patient data, high-performance computing, and causal learning to uncover hidden biological mechanisms of diseases. Aitia's Gemini Digital Twins are instrumental in accelerating research and development in oncology, neurodegenerative disorders, and immunology, aiming to discover novel therapies and expedite the drug development process.
Notable figures associated with Aitia include CEO Colin Hill, who actively promotes the innovative use of AI in drug discovery. The company has formed significant collaborations, such as with Servier to focus on Parkinson’s disease. Aitia's groundbreaking work in Causal AI and Digital Twins has positioned it as a leader in the biotech industry, driving forward the next generation of breakthrough drugs and making a substantial impact on global healthcare research and development.
